-
Posted by
Two Blokes May 18 -
Filed in
Stock
-
3 views
Delcath's commercial execution post-HEPZATO launch has driven impressive revenue growth, positive cash flow, and a shift from speculative to established biotech. Q1 earnings beat expectations with 530% revenue growth, positive EBITDA, and net income, validating the company's scalability and operational progress. Growth drivers include expanding U.S. treatment centers, pipeline development for new indications, and commercial initiatives, though risks remain around execution and clinical milestones.
